| 1. |
Nielsen JB, Crone C, Hultborn H. The spinal pathophysiology of spasticity—from a basic science point of view. Acta Physiol (Oxf), 2007, 189(2): 171-180.
|
| 2. |
Centers for Disease Control and Prevention. What is cerebral palsy? [EB/OL]. [2024-03-03]. https://www.cdc.gov/ncbddd/cp/facts.html.
|
| 3. |
Brashear A, Elovic E. Spasticity: diagnosis and management. 2nd ed. New York: Demos Medical Publishing, 2011: 10-11.
|
| 4. |
Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology, 2013, 80(3 Suppl 2): S13-S19.
|
| 5. |
|
| 6. |
Rodda J, Graham HK. Classification of gait patterns in spastic hemiplegia and spastic diplegia: a basis for a management algorithm. Eur J Neurol, 2001, 8 Suppl 5: 98-108.
|
| 7. |
|
| 8. |
|
| 9. |
|
| 10. |
|
| 11. |
|
| 12. |
|
| 13. |
Collado H, Bensoussan L, Viton JM, et al. Does fascicular neurotomy have long-lasting effects? J Rehabil Med, 2006, 38(4): 212-217.
|
| 14. |
|
| 15. |
|
| 16. |
|
| 17. |
|
| 18. |
|
| 19. |
|
| 20. |
|
| 21. |
Daniels L, Worthingham C. Muscle testingtechniques of manual examination. 4th ed. Philadelphia, London, Toronto: W. B. Saunders Company, 1980: 72-74.
|
| 22. |
|
| 23. |
|
| 24. |
|
| 25. |
|
| 26. |
|
| 27. |
Deltombe T, Lejeune T, Gustin T. Botulinum toxin type A or selective neurotomy for treating focal spastic muscle overactivity? Ann Phys Rehabil Med, 2019, 62(4): 220-224.
|
| 28. |
|
| 29. |
|
| 30. |
Preston DC, Shapiro BE. Electromyography and neuromuscular disorders: clinical-electrodiagnostic-ultrasound correlations. 4th ed. Canada: Elsevier, 2020: 194-196.
|